Clinical

Bristol-Myers Squibb has challenged the recently released report by the Institute for Clinical and Economic Review that evaluates the clinical and cost effectiveness of newer treatments for multiple myeloma.

A new trial from the National Institutes of Health found that a lower systolic blood pressure goal of 120 mm Hg reduces risk of cardiovascular events in geriatric populations.

A new study published in the Journal of the National Cancer Institute has established that institutional volume can significantly influence survival in lung cancer patients receiving chemoradiation.

What we're reading, May 26, 2016: South Carolina passes a 20-week abortion ban, while Georgia's own law faces a new challenge; the FDA delays its decision on a controversial drug for Duchenne muscular dystrophy; and report highlights how Cover Oregon was mishandled.

The bar is set very high in terms of the biosimilar requirement definition, and physicians who are hesitant about substituting biosimilars for treatment should not be worried about the perceived differences, according to Pamela S. Becker, MD, PhD, professor of medicine in the Division of Hematology at the University of Washington School of Medicine.

Oncologists at the Mayo Clinic have developed a more aggressive approach to treating patients with pancreatic cancer-combining surgery, chemotherapy, and radiation, surgical oncologists have been successful in significantly improving survival in a small number of patients.

Two months after the approval of the first biosimilar to infliximab, another Biologics License Application is now under FDA review.

A survey conducted by MaPS/Millward Brown Analytics, on behalf of Memorial Sloan Kettering Cancer Center, has identified multiple concerns of American consumers with cancer clinical trial participation, which could be responsible for the dismal 4% national enrollment rate in clinical trials.

What we're reading, May 24, 2016: Doubt grows about the stability of the Anthem-Cigna merger; use of e-cigarettes and vaping devices stalls in the US; and drugmakers are cautious about developing a Zika virus.